



Commercial, Exchange, and Medicaid formulary changes effective 6/13/22

These additions and changes apply to Commercial and Medicaid formularies and are effective 6/13/22 unless specified below.

Additions:

Leqvio (inclisiran) – Medical benefit, PA and QL Required.

Qulipta (atogepant) – Non-Preferred brand, PA Required and QL of 30 tablets per 30 days.

Tezspire (tezepelumab-ekko) – Medical benefit, PA and QL required.

Tezspire (tezepelumab-ekko) – PA Required and QL of 210mg every 28 days (only applies to Medicaid).

Vabysmo (faricimab-svoa) - Medical benefit, PA and QL required.

Vyvgart (efgartigimod alfa-fcab) - Medical benefit, PA and QL Required.

Enjaymo (sutimlimab-jome) - Medical benefit, PA and QL Required.

Adbry (tralokinumab-ldrm) – Non-Preferred brand, PA Required and QL of 4 syringes per 28 days. (only applies to commercial and exchange)

Cibinqo (abrocitinib) – Non-Preferred brand, PA Required and QL of 30 tablets per 30 days (only applies to commercial and exchange).

Fyarro (sirolimus) – Medical benefit, PA and QL Required.

Zimhi (naloxone pre-filled syringe) – Non-Preferred Brand.

Twyneo (tretinoin/benzoyl peroxide cream) – Non-Formulary for commercial and exchange and PA Required for Medicaid.

Changes:

Dexcom G6 – Changed to Preferred Brand (only applies to commercial and exchange).

Brand Dexilant – Moved to non-formulary (only applies to commercial and exchange).

Novolin 70/30, Novolin N, Novolin R – Remove PA (only applies to Medicaid).

Shingrix (zoster vac) – Correction from previous P&T. Lowered age limit from 50 to **19** years of age.